In advanced prostate cancer, up to 15%–20% of patients develop resistance to androgen receptor–directed (AR-directed) therapies through conversion from an androgen-driven adenocarcinoma to an alternative lineage state such as neuroendocrine prostate cancer (NEPC) (4–6). This evidence concerns the gene AR and adenocarcinoma.